Antithrombotic therapy practices in US hospitals in an era of practice guidelines

Archives of Internal Medicine

Volumn 165, Issue 13, 2005, Pages 1458-1464

  Tapson, Victor F ^a   Hyers, Thomas M ^b   Waldo, Albert L ^c   Ballard, David J ^d   Becker, Richard C ^a   Caprini, Joseph A ^f   Khetan, Roger ^e   Wittkowsky, Ann K ^g   Colgan, Kevin J ^h   Shillington, Alicia C ^h  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b CARE Clinical Research   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d BAYLOR HEALTH CARE SYSTEM   (United States)

^e BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^h EPI Q Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ACUTE HEART INFARCTION; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HIP SURGERY; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TIME SERIES ANALYSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT;

AGED; ANTICOAGULANTS; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INCIDENCE; INPATIENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME; UNITED STATES; WARFARIN;

EID: 23044470227     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.13.1458     Document Type: Article

References (38)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2002;40:1366-1374.
2. Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs. 2000;60:575-595.
3. Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary statement from the National Stroke Association. JAMA. 1999;281:1112-1120.
4. Leary MC, Saver JL. Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis. 2003;16:280-285.
5. Williams GR. Incidence and characteristics of total stroke in the United States. BMC Neurol. 2001;1:2-7.
6. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Circulation. 1996;93:2212-2245.
7. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(suppl):194S-206S.
8. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary: a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231-1266.
9. Allison JJ, Keife CI, Weissman NW, et al. Relationship of hospital teaching status with quality of care and mortality for Medicare patients with acute MI. JAMA. 2000;284:1256-1262.
10. Ayanian JZ, Weissman JS, Chasan-Taber S, Epstein AM. Quality of care for two common illnesses in teaching and nonteaching hospitals. Health Aff (Millwood). 1998;17:194-205.
11. Keeler EB, Rubenstein LV, Kahn KL, et al. Hospital characteristics and quality of care. JAMA. 1992;268:1709-1714.
12. Stafford RS, Radley DC. The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
13. Jencks SF, Huff ED, Cuerdon T. Change in the quality of care delivered to Medicare beneficiaries, 1998-1999 to 2000-2001. JAMA. 2003;289:305-322.
14. Gross CP, Vogel EW, Abahy JD, et al. Factors influencing physicians' reported use of anticoagulation therapy in nonvalvular atrial fibrillation: a cross-sectional survey. Clin Ther. 2003;25:1750-1764.
15. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46.
16. Dhond AJ, Michelena HI, Ezekowitz MD. Anticoagulation in the elderly. Am J Geriatr Cardiol. 2003;12:243-250.
17. Stroke Prevention in Atrial Fibrillation Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. Stroke. 1990;21:538-545.
18. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
19. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: the Veterans Affairs Cooperative Study. N Engl J Med. 1992;327:1406-1412.
20. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
21. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349-355.
22. Man-son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med. 2002;162:541-550.
23. Caplan L. Cerebrovascular disease and stroke. In: Cassel CK, Cohen HJ, Larson EB, et al, eds. Geriatric Medicine. 3rd ed. New York, NY: Spring-Verlag; 1996: 923.
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561-1564.
25. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996;335:696-700.
26. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest. 2004;126:338S-400S.
27. Pellegrini VD, Clement D, Lush-Ehmann C, et al. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop. 1996;333:27-40.
28. Sikorski JM, Hampson WG, Staddon GE. The natural history and aetiology of deep vein thrombosis after total hip replacement. J Bone Joint Surg Br. 1981;63:171-177.
29. Trowbridge A, Boese CK, Woodruff B, et al. Incidence of post-hospitalization proximal deep venous thrombosis after total hip arthroplasty: a pilot study. Clin Orthop. 1994;299:203-208.
30. Lotke PA, Steinberg ME, Ecker ML. Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. Clin Orthop. 1994;299:25-40.
31. Barbash IM, Freimark D, Gottlieb S, et al; Israeli Working Group on Intensive Cardiac Care, Israel Heart Society. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre-hospital administration. Cardiology. 2002;98:141-147.
32. Freimark D, Matetzky S, Leor J, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol. 2002;89:381-385.
33. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
34. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119(suppl):176S-193S.
35. Levine M, Jent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996;334:677-681.
36. Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med. 1996;334:682-687.
37. Lindmarker P, Holmstrom M. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis: a feasibility and health economic study in an outpatient setting. J Intern Med. 1996;240:395-401.
38. Spyropoulos AC. Outpatient protocols for treatment of venous thromboembolism using low-molecular-weight heparin: to treat or not to treat at home. Arch Intern Med. 1999;159:1139-1140.